Transgene and BioInvent: promising results for the oncolytic virus BT-001

Transgene and BioInvent announced promising clinical results for their oncolytic virus BT-001. At the ESMO 2024 congress, data showed that BT-001 reduces tumor size in patients who have failed treatment.

In a patient with heavily pretreated sarcoma, BT-001 stimulated T cell infiltration and PD(L)-1 expression in tumors. In combination with pembrolizumab, clinical responses were observed in 2 of 6 patients.

Data indicate that BT-001 replicates in the tumor without systemic toxicity. The oncolytic virus, alone or in combination with KEYTRUDA®, has shown notable initial efficacy, providing a glimmer of hope for patients with limited treatment options.